Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2001 1
2003 1
2004 4
2005 5
2006 2
2007 3
2008 2
2009 2
2010 3
2011 6
2012 19
2013 33
2014 53
2015 90
2016 92
2017 109
2018 137
2019 125
2020 134
2021 158
2022 140
2023 141
2024 57

Text availability

Article attribute

Article type

Publication date

Search Results

1,165 results

Results by year

Filters applied: . Clear all
Page 1
ATRX, a guardian of chromatin.
Aguilera P, López-Contreras AJ. Aguilera P, et al. Trends Genet. 2023 Jun;39(6):505-519. doi: 10.1016/j.tig.2023.02.009. Epub 2023 Mar 7. Trends Genet. 2023. PMID: 36894374 Free article. Review.
ATRX (alpha-thalassemia mental retardation X-linked) is one of the most frequently mutated tumor suppressor genes in human cancers, especially in glioma, and recent findings indicate roles for ATRX in key molecular pathways, such as the regulation of chromati …
ATRX (alpha-thalassemia mental retardation X-linked) is one of the most frequently mutated tumor suppressor genes in human cancers …
Emerging roles of ATRX in cancer.
Watson LA, Goldberg H, Bérubé NG. Watson LA, et al. Epigenomics. 2015;7(8):1365-78. doi: 10.2217/epi.15.82. Epub 2015 Dec 8. Epigenomics. 2015. PMID: 26646632 Review.
However, over the last years, our knowledge of the epigenetic activities of ATRX has expanded steadily. Recent exciting discoveries have propelled ATRX into the limelight of chromatin and telomere biology, development and cancer research. This review summariz …
However, over the last years, our knowledge of the epigenetic activities of ATRX has expanded steadily. Recent exciting discoveries h …
ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, Zha C, Ye Q, Jiang C, Cai J, Jiang T. Han B, et al. Theranostics. 2020 Feb 10;10(7):3351-3365. doi: 10.7150/thno.41219. eCollection 2020. Theranostics. 2020. PMID: 32194873 Free PMC article.
Therefore, elucidation of the role of ATRX contributing to TMZ resistance in glioma is urgently needed. ...ATRX elicited PARP1 stabilization by the down-regulating of FADD expression via the H3K27me3 enrichment, which was dependent on ATRX/EZH2 complex in TMZ …
Therefore, elucidation of the role of ATRX contributing to TMZ resistance in glioma is urgently needed. ...ATRX elicited PARP1 …
Molecular Pathology of Gliomas.
Galbraith K, Snuderl M. Galbraith K, et al. Surg Pathol Clin. 2021 Sep;14(3):379-386. doi: 10.1016/j.path.2021.05.003. Epub 2021 Jul 8. Surg Pathol Clin. 2021. PMID: 34373090 Review.
Molecular studies have identified features that can enhance diagnosis and provide biomarkers. IDH1/2 mutation with ATRX and TP53 mutations defines diffuse astrocytomas, whereas IDH1/2 mutations with 1p19q loss defines oligodendroglioma. ...
Molecular studies have identified features that can enhance diagnosis and provide biomarkers. IDH1/2 mutation with ATRX and TP53 muta …
Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus.
Floyd W, Pierpoint M, Su C, Patel R, Luo L, Deland K, Wisdom AJ, Zhu D, Ma Y, DeWitt SB, Williams NT, Lazarides AL, Somarelli JA, Corcoran DL, Eward WC, Cardona DM, Kirsch DG. Floyd W, et al. J Clin Invest. 2023 Jul 3;133(13):e149310. doi: 10.1172/JCI149310. J Clin Invest. 2023. PMID: 37200088 Free PMC article.
However, the role of ATRX in tumor development and response to cancer therapies remains poorly understood. ...Translation of these results to patients with ATRX-mutant cancers could enable genomically guided cancer therapy approaches to improve …
However, the role of ATRX in tumor development and response to cancer therapies remains poorly understood. ...Translation of t …
Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure.
Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, Kim HJ, Wongchenko M, Yan Y, Haley B, Cuellar T, Webster J, Alag N, Hegde G, Jackson E, Nance TL, Giresi PG, Chen KB, Liu J, Jhunjhunwala S, Settleman J, Stephan JP, Arnott D, Classon M. Guler GD, et al. Cancer Cell. 2017 Aug 14;32(2):221-237.e13. doi: 10.1016/j.ccell.2017.07.002. Epub 2017 Aug 3. Cancer Cell. 2017. PMID: 28781121 Free article.
Maintenance of phenotypic heterogeneity within cell populations is an evolutionarily conserved mechanism that underlies population survival upon stressful exposures. We show that the genomes of a cancer cell subpopulation that survives treatment with otherwise lethal drugs …
Maintenance of phenotypic heterogeneity within cell populations is an evolutionarily conserved mechanism that underlies population survival …
Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
Bogumil H, Sill M, Schrimpf D, Ismer B, Blume C, Rahmanzade R, Hinz F, Cherkezov A, Banan R, Friedel D, Reuss DE, Selt F, Ecker J, Milde T, Pajtler KW, Schittenhelm J, Hench J, Frank S, Boldt HB, Kristensen BW, Scheie D, Melchior LC, Olesen V, Sehested A, Boué DR, Abdullaev Z, Satgunaseelan L, Kurth I, Seidlitz A, White CL, Ng HK, Shi ZF, Haberler C, Deckert M, Timmer M, Goldbrunner R, Tauziède-Espariat A, Varlet P, Brandner S, Alexandrescu S, Snuderl M, Aldape K, Korshunov A, Witt O, Herold-Mende C, Unterberg A, Wick W, Pfister SM, von Deimling A, Jones DTW, Sahm F, Sievers P. Bogumil H, et al. Acta Neuropathol. 2023 May;145(5):667-680. doi: 10.1007/s00401-023-02558-0. Epub 2023 Mar 18. Acta Neuropathol. 2023. PMID: 36933012 Free PMC article.
Glioneuronal tumors are a heterogenous group of CNS neoplasms that can be challenging to accurately diagnose. Molecular methods are highly useful in classifying these tumors-distinguishing precise classes from their histological mimics and identifying previously unrecogniz …
Glioneuronal tumors are a heterogenous group of CNS neoplasms that can be challenging to accurately diagnose. Molecular methods are h …
Mutant ATRX: uncovering a new therapeutic target for glioma.
Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, Núñez FJ, Méndez FM, Núñez F, Lowenstein PR, Castro MG. Haase S, et al. Expert Opin Ther Targets. 2018 Jul;22(7):599-613. doi: 10.1080/14728222.2018.1487953. Epub 2018 Jun 20. Expert Opin Ther Targets. 2018. PMID: 29889582 Free PMC article. Review.
We focus on the salient consequences of ATRX mutations in cancer, from a clinical to a molecular point of view, focusing on both adult and pediatric glioma. ...We anticipate new treatments and clinical approaches will emerge for glioma and other cancer types …
We focus on the salient consequences of ATRX mutations in cancer, from a clinical to a molecular point of view, focusing on bo …
ATRX and DAXX: Mechanisms and Mutations.
Dyer MA, Qadeer ZA, Valle-Garcia D, Bernstein E. Dyer MA, et al. Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):a026567. doi: 10.1101/cshperspect.a026567. Cold Spring Harb Perspect Med. 2017. PMID: 28062559 Free PMC article. Review.
Recent genome sequencing efforts in a variety of cancers have revealed mutations and/or structural alterations in ATRX and DAXX, which together encode a complex that deposits histone variant H3.3 into repetitive heterochromatin. ...Here we review the functions of …
Recent genome sequencing efforts in a variety of cancers have revealed mutations and/or structural alterations in ATRX and DAX …
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
Hu C, Wang K, Damon C, Fu Y, Ma T, Kratz L, Lal B, Ying M, Xia S, Cahill DP, Jackson CM, Lim M, Laterra J, Li Y. Hu C, et al. Neuro Oncol. 2022 Jun 1;24(6):888-900. doi: 10.1093/neuonc/noab292. Neuro Oncol. 2022. PMID: 34951647 Free PMC article.
BACKGROUND: ATRX inactivation occurs with IDH1R132H and p53 mutations in over 80% of Grades II/III astrocytomas. ...This paper examines how ATRX loss contributes to the malignant and immunosuppressive phenotypes of IDH1R132H/p53mut glioma cells and xenografts. ...
BACKGROUND: ATRX inactivation occurs with IDH1R132H and p53 mutations in over 80% of Grades II/III astrocytomas. ...This paper examin …
1,165 results

Searches related to "atrx cancer"